Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role
Φόρτωση...
Ημερομηνία
Συγγραφείς
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Exp Neurol
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
Experimental autoimmune neuritis (EAN) is a CD4(+) T-cell-mediated demyelinating disease of the peripheral nervous system (PNS). We examined the effect of recombinant mouse interleukin 17 (rmIL-17) on chronic EAN induced in Lewis rats by inoculation of P2 57-81 peptide in Freund's complete adjuvant. Animals were treated nasally for 6 days with either 0.1 or 0.9 microg/rat/day rmIL-17 from the onset of neurological signs, i.e., days 9 to 14 postimmunization (p.i.). Prolonged follow-up demonstrated a chronic course in control and rmIL-17-treated rats. Treated rats had more severe disease initially (days 18-36 p.i.) with a stronger enhancing effect observed with the higher rmIL-17 dose. At day 19 rmIL-17-treated rats showed increased infiltration of inflammatory cells into the sciatic nerve, more severe demyelination, augmented proliferation of regional lymph node cells, and increased serum levels of tumor necrosis factor-alpha. After the initial phase of disease enhancement the IL-17-treated EAN rats improved gradually and ultimately recovered completely, whereas the control EAN rats remained affected until the end of the observation (day 120 p.i.). The lower dose of rmIL-17 induced an earlier recovery from clinical deficits than the higher one. The results indicate that IL-17 plays an immunoregulatory role in chronic EAN which could have implications for immunomodulatory treatments of chronic autoimmune disease of the PNS.
Περιγραφή
Λέξεις-κλειδιά
Acute Disease, Administration, Intranasal, Animals, Cells, Cultured, Chronic Disease, Disease Progression, Dose-Response Relationship, Drug, Immunohistochemistry, Interleukin-17/administration & dosage/*immunology, Leukocytes, Mononuclear/cytology/drug effects, Lymphocyte Activation/drug effects/immunology, Male, Mice, Myelin P2 Protein/immunology, Neuritis, Autoimmune, Experimental/*immunology/pathology, Peptide Fragments/immunology, Rats, Rats, Inbred Lew, Recombinant Proteins/administration & dosage/immunology/therapeutic use, Sciatic Nerve/drug effects/pathology, Tumor Necrosis Factor-alpha/metabolism
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/10785455
http://ac.els-cdn.com/S0014488600973576/1-s2.0-S0014488600973576-main.pdf?_tid=bcff35d1260c14239710b3ce2f6f4eec&acdnat=1332844618_80dd581d1d066ba347bdc6937731c840
http://ac.els-cdn.com/S0014488600973576/1-s2.0-S0014488600973576-main.pdf?_tid=bcff35d1260c14239710b3ce2f6f4eec&acdnat=1332844618_80dd581d1d066ba347bdc6937731c840
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής